New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PFE;ACT;JNJ;NVS;TEVA;MYL;GNK;BMY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 30, 2015
09:04 EDTTEVATeva says R&D update meeting will be held before year-end
Subscribe for More Information
08:25 EDTTEVATeva CEO says 'too early' to provide specifics on other potential deals
08:11 EDTTEVATeva CEO says Allergan deal financing commitment expected in next few days
Subscribe for More Information
07:04 EDTTEVATeva reaffirms 2015 revenue outlook $19B-$19.4B, consensus $19.47B
Subscribe for More Information
07:03 EDTTEVATeva raises 2015 EPS outlook to $5.15-$5.40 from $5.05-$5.35
Subscribe for More Information
07:02 EDTTEVATeva reports Q2 EPS $1.43, consensus $1.27
Subscribe for More Information
05:48 EDTMYLStocks with implied volatility movement; SUNE MYL
Subscribe for More Information
July 29, 2015
19:08 EDTBMYBristol-Myers enters immuno-oncology collaboration with Kyowa Hakko Kirin
Kyowa Hakko Kirin and Bristol-Myers Squibb announced that the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1/2 combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo, a PD-1 immune checkpoint inhibitor. The study, which will be conducted in the U.S., will focus on evaluating the safety, tolerability and anti-tumor activity of combining mogamulizumab and Opdivo as a potential treatment option for patients with advanced or metastatic solid tumors. Prior to this agreement, Kyowa Hakko Kirin, Bristol-Myers Squibb and Ono Pharmaceutical entered into a clinical trial collaboration agreement to study the combination of mogamulizumab and Opdivo in Japan. Mogamulizumab and Opdivo are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system.
14:49 EDTGSKGlaxoSmithKline probing new bribery allegations in Romania, Reuters reports
Subscribe for More Information
13:11 EDTMYLMylan recent weakness a buying opportunity, says BTIG
Subscribe for More Information
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
08:00 EDTGSKGlaxoSmithKline reports Q2 global pharmaceuticals revenue GBP2.98B, down 12%
Reports Q2 HIV revenue GBP559M, up 59%. Reports Q2 Pharmaceuticals revenue GBP3.54B, down 6%, and vaccines revenue GBP814M, up 11%. Consumer healthcare sales were GBP1.51B, up 51% year over year.
07:58 EDTGSKGlaxoSmithKline sees FY16 core EPS to grow in double digits
Subscribe for More Information
07:57 EDTGSKGlaxoSmithKline reaffirms FY15 core EPS declining at high-teens percentage rate
Subscribe for More Information
07:54 EDTTEVATeva resumed with an Overweight at Morgan Stanley
Target $85.
07:54 EDTGSKGlaxoSmithKline reports Q2 adjusted EPS 17.3p, consensus 16.78p
Subscribe for More Information
07:02 EDTMYLMylan's Perrigo acquisition receives clearance from European Commission
Subscribe for More Information
07:02 EDTTEVAIgnyta announces FDA clearance of IND for RXDX-107
Subscribe for More Information
06:50 EDTPFEPfizer CEO: Company has 'sufficient courage' to pursue takeovers, FT says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use